论文部分内容阅读
Objective Hepatocellular carcinoma(HCC)is one of the most common malignancies and lethal neoplasm worldwide with rapidly increasing incidence.Sorafenib was firstly approved for the treatment of advanced HCC by the European Medicines Agency and U.S.Food and Drug Administration in the last decade.However,low overall response rate,primary and acquired drug resistance are the major factors hampering the usage of sorafenib clinically.Therefore,the underlying mechanisms for sorafenib resistance need to be explored.